MARKET

TMCI

TMCI

TREACE MEDICAL CONCEPTS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.61
+0.58
+2.15%
After Hours: 27.61 0 0.00% 16:00 07/27 EDT
OPEN
27.00
PREV CLOSE
27.03
HIGH
29.01
LOW
26.35
VOLUME
227.95K
TURNOVER
--
52 WEEK HIGH
37.17
52 WEEK LOW
24.25
MARKET CAP
1.46B
P/E (TTM)
-177.6705
1D
5D
1M
3M
1Y
5Y
Treace to Report Second Quarter 2021 Financial Results on August 5, 2021
Treace Medical Concepts, Inc. ("Treace") (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial...
GlobeNewswire · 6h ago
How Much Of Treace Medical Concepts, Inc. (NASDAQ:TMCI) Do Insiders Own?
The big shareholder groups in Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) have power over the company. Large...
Simply Wall St. · 4d ago
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2)
Benzinga · 06/03 12:23
Morgan Stanley Maintains Equal-Weight on Treace Medical Concepts, Raises Price Target to $32
Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Equal-Weight and raises the price target from $30 to $32.
Benzinga · 05/26 12:54
--Morgan Stanley Adjusts Treace Medical Concepts' Price Target to $32 From $30, Keeps Equal-Weight Rating
MT Newswires · 05/26 11:38
BRIEF-Treace Medical Concepts Reports First Quarter 2021 Financial Results
reuters.com · 05/25 23:17
Treace Medical Concepts EPS in-line, beats on revenue
Treace Medical Concepts (TMCI): Q1 GAAP EPS of -$0.07 in-line.Revenue of $18.71M (+66.2% Y/Y) beats by $0.06M.Treace Medical Concepts projects revenue for the full year 2021 to range from $87
Seekingalpha · 05/25 20:24
Treace Medical Concepts Q1 EPS $(0.07) Down From $(0.05) YoY, Sales $18.70M Up From $11.30M YoY
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $18.70 million in
Benzinga · 05/25 20:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TMCI. Analyze the recent business situations of TREACE MEDICAL CONCEPTS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TMCI stock price target is 35.67 with a high estimate of 38.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 1
Institutional Holdings: 20.00K
% Owned: 0.04%
Shares Outstanding: 52.75M
TypeInstitutionsShares
Increased
0
0
New
1
20.00K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.85%
Healthcare Equipment & Supplies
+0.62%
Key Executives
Chairman/Director
James Treace
Chief Executive Officer/Founder/Director
John Treace
Chief Financial Officer
Mark Hair
Chief Human Resource Officer
Daniel Owens
Senior Vice President/Director of Sales
Dipak Rajhansa
Senior Vice President/Director of Marketing
Sean Scanlan
Senior Vice President
Joe Ferguson
Chief Compliance Officer/Secretary
Jaime Frias
Independent Director
John Bakewell
Independent Director
F. Barry Bays
Independent Director
Lawrence Hamilton
Independent Director
Richard Mott
Independent Director
Thomas Timbie
No Data
About TMCI
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company. The Company is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The Company's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The Company's brands include Lapiplasty, Fast Grafter and Plantar Python.

Webull offers kinds of Treace Medical Concepts Inc stock information, including NASDAQ:TMCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TMCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TMCI stock methods without spending real money on the virtual paper trading platform.